CAM
UTHR icon

Claret Asset Management’s United Therapeutics UTHR Stock Holding History

Claret Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
414
-392
-49% -$221K 0.02% 427
2026
Q1 		$478K Hold
806
– – 0.06% 120
2025
Q4 		$393K Sell
806
-2
-0.2% -$931 0.05% 133
2025
Q3 		$339K Sell
808
-11
-1% -$3.7K 0.04% 139
2025
Q2 		$235K Buy
819
+131
+19% +$39.2K 0.03% 258
2025
Q1 		$212K Hold
688
– – 0.03% 258
2024
Q4 		$243K Buy
688
+5
+0.7% +$1.84K 0.04% 193
2024
Q3 		$245K Buy
683
+4
+0.6% +$1.35K 0.04% 169
2024
Q2 		$216K Buy
+679
New +$180K 0.04% 157

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Claret Asset Management's UTHR Position: Q2 2026 in Review

Claret Asset Management reduced its United Therapeutics (UTHR) stake by 49% in Q2 2026, selling an estimated $221K and leaving 414 shares worth $224K. The position accounts for 0.02% of the portfolio, ranked #427.

Claret Asset Management first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $478K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Claret Asset Management held 414 shares of United Therapeutics worth $224K as of Q2 2026.
  • Claret Asset Management sold 392 United Therapeutics shares in Q2 2026, an estimated $221K.
  • United Therapeutics made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #427 holding.
  • Claret Asset Management first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Claret Asset Management's United Therapeutics position peaked at $478K in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.